Robust detection of oncometabolic aberrations by $^1$H-$^{13}$C heteronuclear single quantum correlation in live cells and intact tumors ex-vivo

Yasaman Barekatain¹, Victoria C Yan¹, Kenisha Arthur¹, Jeffrey J. Ackroyd¹, Sunada Khadka¹, John De Groot⁴, Jason T. Huse⁵, Florian L. Muller¹#

¹Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA
⁴Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
⁵Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

#Correspondence should be addressed to Florian L. Muller, Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054 Tel: (713) 794 5216, E-mail: fmuller@mdanderson.org; aettius@aol.com

Keywords: genomic deletions, metabolism, metabolomics, targeted therapy
Abstract

Extensive efforts have been made to use non-invasive $^1$H magnetic resonance (MR) spectroscopy to quantify metabolites that are diagnostic of specific disease states. Within the realm of precision oncology, these efforts have largely centered on quantifying 2-hydroxyglutarate (2-HG) in tumors harboring isocitrate dehydrogenase 1 ($IDH1$) mutations. As many metabolites have similar chemical shifts, the resulting $^1$H spectra of intact biological material are highly convoluted, limiting the application of $^1$H MR to high abundance metabolites. Hydrogen-Carbon Heteronuclear single quantum correlation $^1$H-$^1^3$C HSQC is routinely employed in organic synthesis to resolve complex spectra but has received limited attention for biological studies. Here, we show that $^1$H-$^1^3$C HSQC offers a dramatic improvement in sensitivity compared to one-dimensional (1D) $^1^3$C NMR and dramatic signal deconvolution compared to 1D $^1$H spectra in an intact biological setting. Using a standard NMR spectroscope without specialized signal enhancements features such as magic angle spinning, metabolite extractions or $^1^3$C-isotopic enrichment, we obtain well-resolved 2D $^1$H-$^1^3$C HSQC spectra in live cancer cells, in ex-vivo freshly dissected xenografted tumors and resected primary tumors. We demonstrate that this method can readily identify tumors with specific genetic-driven oncometabolite alterations such as $IDH$ mutations with elevation of 2-HG as well as $PGD$-homozygously deleted tumors with elevation of gluconate. These data support the potential of $^1$H-$^1^3$C HSQC as a non-invasive diagnostic tool for metabolic precision oncology.
Introduction

Metabolic vulnerabilities are emerging as viable therapeutic targets within the framework of precision oncology\textsuperscript{1-3}. Well-studied examples of such aberrations include tumors that have mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. As key drivers of tumorigenesis in diverse cancers such as glioma, cholangiocarcinoma, and leukemia, IDH1/2 mutations have been the foci of a number of experimental and clinical studies\textsuperscript{4}. Both cytoplasmic IDH1 and mitochondrial IDH2 enzymes catalyze the conversion of isocitrate to \(\alpha\)-ketoglutarate\textsuperscript{5}. Recurrent mutations in the active site of these enzymes result in a neomorphic activity that enables NADPH-dependent reduction of \(\alpha\)-ketoglutarate to the oncometabolite R-2-hydroxyglutarate (2-HG)\textsuperscript{6,7}. Thus, the accumulation of 2-HG inside IDH1/2 mutant tumors can reach millimolar level and is the molecular hallmark of this mutation. In glioma, patients harboring \textit{IDH} mutations have better prognoses compared to the \textit{IDH}-wildtype group\textsuperscript{8,9}, and would be the candidate for targeted therapies such as \textit{IDH1} mutant inhibitor, AGI-120 (NCT03564821).

The demand driving the development of drugs targeting tumor metabolism extends beyond \textit{IDH} mutations. An emerging metabolic vulnerability-based precision oncology is collateral lethality\textsuperscript{10,11}. Homozygous deletion of major tumor suppressor genes can result in the collateral deletion of chromosomal neighboring metabolic housekeeping genes such as the pentose phosphate shunt enzyme 6-phosphogluconate dehydrogenase (\textit{PGD}) at the 1p36 locus\textsuperscript{10-12}. PGD enzyme catalyzes the oxidative conversion of 6-phosphogluconate (6-PG) in the oxidative arm of the pentose phosphate pathway, and its deletion results in >100-fold increased accumulation of 6-phosphogluconate and its
hydrolysis product gluconate\textsuperscript{12}. As tumors harboring \textit{PGD} deletions are exceptionally sensitive to the clinical-stage (NCT03291938) oxidative phosphorylation (OxPhos) inhibitor, IACS-010759\textsuperscript{12}, quantification of 6-PG levels in tumors can be directly diagnostic of \textit{PGD}-deletion status and concomitant sensitivity to IACS-010759.

A persistent problem for the full realization of the clinical potential of precision oncology, consists of the timely and convenient identification of the subsets of patients with the appropriate genetic alteration for each specific molecular targeted agent. \textit{IDH} point mutations and the deletion of \textit{PGD} result in the accumulation of 2-HG and 6-PG, respectively. They constitute representative examples of different targetable genomic alterations, which result in millimolar accumulation of specific metabolites compared to normal brain or wildtype tumors. In principle, such millimolar accumulation of metabolites should be diagnosable with magnetic resonance spectroscopy (MRS)\textsuperscript{13-15}. Attempts have been made to diagnose \textit{IDH} mutant status by \textsuperscript{1}H MRS\textsuperscript{16-18}. However, in practice, there are two limitations to the implementation of this technique to diagnose \textit{IDH} mutant and \textit{PGD} deletion status. First, the \textsuperscript{1}H spectrum of tumors is highly convoluted due to the overlapping chemical shifts of different molecules and signals from informative metabolites, like 2-HG, can be obscured by highly abundant common metabolites\textsuperscript{19,20}. Second, even employing the best water suppression pulse sequences, one cannot detect signals from metabolites that have chemical shifts close to the overwhelming water signal in the middle (4.7 ppm) of the spectrum\textsuperscript{21}. Because of these biological and technical limitations, as of 2019, no \textsuperscript{1}H-MRS protocol for diagnosis of \textit{IDH}-mutant tumors is FDA approved, or CMS reimbursed.
Here, we demonstrate that it is possible to overcome the specificity-limitations of $^1$H MRS through $^1$H-$^{13}$C HSQC. This technique de-convolutes the spectrum into 2 dimensions and harnesses the differences in both $^1$H and $^{13}$C chemical shifts to resolve the signal-peaks of closely related chemical species. Rather than merely peaks in a 1D spectrum, the identity of specific metabolites is characterized by a pattern or constellation of C-H HSQC peaks in a 2D area. The sensitivity of this technique is dramatically higher than standard $^{13}$C-spectroscopy, as the signal is ultimately generated through $^1$H-magnetization as well as ultimately read in the $^1$H channel. We demonstrated that a phase-sensitive HSQC pulse sequence with short scan times enables detection of 2-HG and 6-phosphogluconate/gluconate in live cancer cells as well as tumors ex-vivo; this way, we can reliably identify tumors/cell lines that carry IDH-point mutations or PGD-homozygous deletions. This was achieved without signal enhancing devices (e.g., spinning), $^{13}$C-isotope enrichment, or biochemical metabolite extraction – all despite the high magnetic in-homogeneities inherent in live cells or tumor chunks. These data suggest immediate utility in the setting of just-in-time diagnosis during tumor resection as well as the potential for use in non-invasive MRS setting in vivo.

Results
Convolution of $^1$H spectra hinders robust detection of oncometabolites in intact biological samples. To provide a yardstick for the usefulness of $^1$H-$^{13}$C HSQC in the intact biological setting, we first performed detailed studies with conventional 1D $^1$H nuclear magnetic resonance (NMR). We performed proof-of-principal experiments in a
standard NMR spectrometer (see methods) with standard 5 mm NMR tubes. To provide a solid point of reference, analysis of the $^1$H spectrum of the 2-HG pure chemical standard in 10% D$_2$O phosphate-buffered saline (PBS) was conducted under the exact experimental conditions subsequently used for biological experiments. The $^1$H spectrum of the 2-HG standard showed a quartet at 3.92-3.95 ppm for the H2, a convoluted multiplet at 2.11-2.23 ppm for H4 and H4’, and multiplets at 1.71-1.79 ppm and 1.87-1.95 ppm for H3 and H3’ (Supplementary Fig. S1C). We then took $^1$H scans of live mutant $iD$H1 cancer cells (HT-1080, NHA m$ID$H1, SNU-1079 and COR-L105; for a full description of the cell types and mutations, see methods). As a negative control, we also took $^1$H NMR scans of $iD$H wildtype cell lines treated with the IDH1 inhibitor AGI-519823, which inhibits the production of 2-HG. We found that 2-HG peaks are indistinct, due to broadening and overlap with peaks from other highly abundant metabolites in normal brain and wildtype $iD$H tumors (Supplementary Fig. S1d-S1j). For example, glutamine, glutamate, and GABA have chemical shifts close to H4 and H4’ of 2-HG, while NAA resonances close to frequencies of H3 and H3’ protons of 2-HG. Lactate, myo-inositol and phosphocholine and choline have chemical shifts close to H2 peak of 2-HG$^{19}$. Though there are vague hints that peaks may be attributed to 2-HG upon post-hoc analysis, their small signal-to-noise ratio (SNR), broadness, and low amplitude compared to neighboring peaks, in no way, enable confident discrimination between $iD$H-mutant and WT tumors without previous genetic assignment. Furthermore, the peak broadening is likely to be worse in the MRS setting in vivo, making the confidence in these peaks for specific identification of 2-HG/$iD$H mutant tumors even less appealing.
$^1$H-$^{13}$C HSQC allows reliable detection of 2-HG and typing of $IDH$ mutant status in intact biological samples even with natural abundance $^{13}$C. To resolve the issue of spectral overlap, we reasoned that metabolites with similar $^1$H NMR shifts may be discriminated by the differences in their $^{13}$C NMR shifts via 2D $^1$H-$^{13}$C HSQC. After screening various pulse sequences available in Bruker TopSpin (3.5) MD Anderson's NMR core, we found that the phase-sensitive HSQCETGPSISP3.2 pulse program$^{24-26}$ yields high SNR, sharp peaks in the $^{13}$C axis, and distinguishes between positive phase (CH$_3$ and CH peaks) from negative phase (CH$_2$ peaks) — shown as different colors (Fig. 1a). Together, these qualities provide an additional layer of confidence in correct metabolite-peak assignments. Using this pulse program, we first characterized the $^1$H-$^{13}$C HSQC spectrum of the 2-HG chemical standard under the same conditions that we would apply to live cells (Fig. 1a). The 2D $^1$H-$^{13}$C HSQC spectrum shows resonances for all protons, which directly bound to $^{13}$C (J1 coupling), with the chemical shift for $^1$H in the x-axis and $^{13}$C in the y-axis. Thus, the spectrum completely omits non-H-bonded $^{13}$C atoms such as carbonyls in carboxylic acids. The H-C2(-OH) of 2-HG resonates at ($^1$H chemical shift, $^{13}$C chemical shift) = (3.92 ppm, 72 ppm) and appears with a positive phase (brown in Fig. 1b). Only directly C-bonded H-atom contributes to this signal; thus, the proton on the oxygen remains occulted. The H-C4-H protons of 2-HG resonate at (2.157 ppm, 33 ppm) and appear in the negative phase (pink in Fig. 1b). Finally, the H-C3-H resonances appear as two distinct peaks with chemical shifts of (31 ppm, 1.73 ppm) and (31 ppm, 1.89 ppm) with a negative phase. From this $^1$H-$^{13}$C HSQC spectrum standard, we also extracted the $^1$H axis projections for each resonance in the 2D spectrum (Supplementary Fig. S2), which provides better visualization of the positive or negative phasing for each
peak which, by extension, indicates the level of substitution at each corresponding carbon.

Having established a reference 2-HG HSQC spectrum, we then employed this pulse sequence to acquire the \(^1\)H\(^{13}\)C HSQC spectrum of live \(IDH1\) mutant cancer cells (HT-1080) re-suspended in phosphate-buffered saline with 10% \(D_2O\) in a standard 5 mm NMR tube with a 500 MHz NMR. HT-1080 cells harbor the R132C \(IDH1\) mutation and overproduce 2-HG\(^27\), which we verified here by mass spec (Supplementary Fig. S1b). Fig. 1b shows the \(^1\)H\(^{13}\)C HSQC spectrum of live HT-1080 cells acquired over a period of 30 minutes. In this spectrum, we assigned 2-HG peaks, as learned from the reference standard (Fig. 1a). All 2-HG peaks were clearly visible in the \(^1\)H\(^{13}\)C HSQC spectrum of live HT-1080 cells. The C2-H peak of 2-HG appears with a positive phase at (3.92 ppm, 72 ppm). This peak of 2-HG has a chemical shift close to the high abundant metabolite myo-inositol at (3.96 ppm, 72 ppm), which is present in all cancer cell lines examined (Supplementary Fig. S1b). Therefore, it makes differentiating the C2-H peak of 2-HG apart from the C-H peak of myo-inositol hard in \textit{in-vivo} and \textit{ex-vivo} experiments. The negatively phased H-C4-H peaks of 2-HG appears at (2.15 ppm, 33.5 ppm). Finally, H-C3-H doublet of 2-HG appear at (1.73 ppm, 31 ppm) and (1.89 ppm, 31 ppm) with the negative phase.

Additional to the 2-HG peaks, the spectrum shows peaks for other abundant metabolites such as lactate, myo-inositol, choline, fatty acids, and many others. To make sure we correctly assigned 2-HG peaks in the spectrum, and as the negative control, we scanned
live HT-1080 cells treated with 10 µM mutant \textit{IDH1} inhibitor, AGI-5198\textsuperscript{23}. The AGI-5198 inhibitor has an IC50 of 160 nM for R132C \textit{IDH1} mutant and IC50 of > 100 µM for \textit{IDH1} wildtype\textsuperscript{23}. Therefore, treating \textit{IDH1} mutant cells with the non-toxic concentration of AGI-5198 inhibitor results in a significant reduction in 2-HG level, which was confirmed by doing mass-spectroscopy on our HT-1080 cells treated with this inhibitor (Supplementary Fig. S1b). Figure 1c shows the spectrum of live HT-1080 cells treated with 10 µM AGI-5198 for 48 hrs. Comparing the HT-1080 cells spectrum (Fig. 1b) with the spectrum of HT-1080 cells treated with AGI-5198 (Fig. 1c) revealed that only one pair of peaks was sufficiently distinct from other metabolites to be diagnostically useful. Since the C2-H peak of 2-HG is convoluted with the peak of myo-inositol at (3.96 ppm, 72 ppm), the difference in the HSQC spectrum of HT-1080 cells and HT-1080 cells treated with the inhibitor is indistinguishable at this region of the spectrum. Also, The H-C4-H peak of 2-HG at (2.15 ppm, 33.5 ppm) is obscured by the fatty acid peak at the same location. Only the H-C3-H peaks of 2-HG were not obstructed by peaks from common high-abundance metabolites. The dashed red box in the spectrum shows where we are expecting to see H-C3-H peaks of 2-HG in the spectrum.

To further confirm our observation that the detection of H-C3-H peaks (1.73 ppm, 31 ppm) and (1.89 ppm, 31 ppm) of 2-HG are unique to \textit{IDH1} mutant cells, we also acquired the spectrum of live \textit{IDH1} wildtype cells (Fig 1d, Table 1 and Supplementary Fig. S3). Comparing the spectrum of \textit{IDH1} wildtype with \textit{IDH1} mutant cells, we observed that H-C3-H peaks of 2-HG are absent in the \textit{IDH1} wildtype spectra. As we observed in the
spectrum of HT-1080 cells treated with mutant IDH1 inhibitor, C2-H and H-C3-H peaks of 2-HG were convoluted by myo-inositol and fatty acid peaks. Moreover, we acquired $^1$H-$^{13}$C HSQC spectrum of other IDH1 mutant and wildtype cells to confirm that we can type IDH1 mutation status of cells by detecting the H-C3-H peaks of 2-HG. Supplementary Figures S3a, S3c, and S3e show the unique detection of H-C3-H peaks of 2-HG in live NHA mIDH1 cells (mutation in R132H), live SNU-1079, and live COR-L105 (mutation in R132C) cells, while H-C3-H peaks were not detected in spectra of live NHA (control for NHA mIDH1) and live SNU-1079 cells treated with 10 µM AGI-5198 inhibitor under the same experimental conditions. Table 1 shows the list of cells in-vitro and ex-vivo xenografted tumors that we acquired $^1$H-$^{13}$C HSQC spectra on, the origin of cell lines, their IDH1 mutation status, and whether we detected H-C3-H peaks on their spectrum or not. To the best of our knowledge, this phase-sensitive HSQC pulse sequence has not been applied to biological experiments, and certainly not for diagnosing specific oncometabolites.

We looked at $^1$H projection of 2D HSQC spectra to more robustly determined signal to noise ratios and quantitatively compare experimental conditions that alter levels of 2-HG (Supplementary Fig. S3). For the 31 ppm chemical shift, we are observed as expected negatively-phased doublet associated with H-C3-H peaks of 2-HG in the 2D spectra (Supplementary Fig. S3f). Based on this figure, the $^1$H projections of IDH1 mutant cells show negative doublet at 1.74 ppm and 1.89 ppm, the same as the $^1$H projection of the 2-HG standard extracted from the same row of the 2-HG HSQC spectrum. These
doublets are absent in IDH1 mutant cells treated with mutant IDH1 inhibitor and IDH1 wildtype cells.

To further confirm that the detection of H-C3-H peaks of 2-HG is the marker of the IDH1 mutation status, we scanned intact IDH1 mutant and wildtype xenografted tumors as well as intact human primary glioblastoma multiforme (GBM) cells. Figure 2a shows the $^1$H-$^{13}$C HSQC spectrum of the freshly dissected R132C IDH1 mutant xenografted tumor (HT-1080). H-C3-H peaks of 2-HG at (1.78 ppm, 31 ppm) and (1.93 ppm, 31 ppm) are readily detectable in this spectrum. However, these two peaks are absent in the spectra of freshly dissected IDH1 wildtype xenografted tumors (Fig. 2b and Fig. 2c). Moreover, H-C3-H peaks are absent in the spectrum of the intact normal mouse brain (Fig. 2d).

We also looked at the spectra of intact IDH1 mutant and wildtype human GBMs (Fig. 3). We confirmed the IDH1 mutation status, as well as high accumulation of 2-HG in the IDH1 mutant tumor by mass spectroscopy (Fig. 3b). Then, we looked at the spectrum of the intact IDH1 mutant human GBM, where we were able to detect H-C3-H peaks of 2-HG. These two peaks were absent in the spectrum of the intact IDH1 wildtype human GBM. Like cells spectra, the C2-H peak of 2-HG in IDH1 mutant tumors was convoluted to the C-H peak of myo-inositol, which made detection of C2-H peak of 2-HG in-vivo hard and non-specific. H-C2-H peaks of 2-HG were also obscured in an ex-vivo experiment with another metabolite and did not show unique intensity in IDH1 mutant tumors. Taken together, these data indicate that $^1$H-$^{13}$C HSQC detection of the negatively phased
doublet peaks of 2-HG at (1.73 ppm, 30.9 ppm) and (1.89 ppm, 30.8 ppm) are a robust biomarker IDH1-mutant status in biological samples.

**HSQC $^1$H-$^{13}$C allows concomitant screening for diverse oncometabolite aberrations.** Our group has a running interest in passenger homozygous deleted metabolic enzymes as points of selective vulnerability for precision oncology$^{11,12}$. Homozygous deletion of metabolic enzymes stands to cause accumulation of metabolites upstream of the deleted enzymes, and as such, be detectable by NMR based methods. Having demonstrated that it is possible to genetically type a tumor based on metabolite levels by $^1$H-$^{13}$C HSQC, we sought to expand its utility to additional oncometabolite aberrations such as those induced by passenger homozygous deletions of metabolic enzymes. A critical advantage of the $^1$H-$^{13}$C HSQC spectrum is that the 2D peak patterns for specific metabolites are constellation-like and can serve as the fingerprint identification. The advantage of this compared to $^1$H is that subtle changes in chemical shifts of specific molecules can happen due to biological microenvironmental changes, such as ionic strength and pH changes, which confuse the assignment of peaks to a specific molecule. With $^1$H-$^{13}$C HSQC, the arrangement of peaks even shifted in 1D $^1$H by microenvironmental effects are unlikely to affect the constellation pattern of peaks in the 2D $^1$H-$^{13}$C HSQC. This advantage is perfectly illustrated in the detection of elevated gluconate in tumors with PGD-homozygous deletion. Figure 4a shows the oxidative pentose phosphate pathway (PPP) where glucose 6-phosphate produced from glycolysis enters into the oxidative arm of PPP and further converts to the 6-PG. PGD is the enzyme that is responsible for the oxidation of 6-PG to ribose 5-phosphate. The homozygous
deletion of PGD results in the accumulation, i.e. 100-fold elevation of 6-PG and its hydrolysis product gluconate (Supplementary Fig. S4) compared to PGD-intact. Thus, the detection of 6-PG/gluconate can serve as the identification for tumors with this genomic alternation. Although both gluconate and 6-PG are elevated in the PGD-deleted cells, the concentration of gluconate is higher than 6-PG, which makes it suitable to detect with MRS. However, the detection of gluconate from the $^1$H spectrum is challenging because all the protons of gluconate molecules are C-H, which is a common chemical group in all sugars and resonates very close to the water signal in 4.7 ppm (Supplementary Fig. S4). Therefore, peak patterning in the 2D $^1$H-$^{13}$C HSQC is ideally suited with the detection of gluconate and typing the PGD-deleted tumors. In the Fig. 4b, the $^1$H-$^{13}$C HSQC of gluconate standard with specific carbon hydrogen is shown using the phase sensitive $^1$H-$^{13}$C HSQC in which the CH group appears in the positive phase, and the CH$_2$ group appears in the negative phase. The C2-H peak of gluconate resonates at (4.03 ppm, 74 ppm), the C3-H peak resonates at (3.93 ppm, 71 ppm), the C4-H peak is at (3.66 ppm, 72.5 ppm), the C5-H peak is (3.66 ppm, 71 ppm), and H-C6-H peaks are at (3.55 ppm, 63 ppm) and (3.74 ppm, 63 ppm). Figures 4c - 4f show $^1$H-$^{13}$C HSQC spectra of ex-vivo xenografted tumors and the normal mouse brain. The black dashed box in each spectrum magnifies the region where gluconate peaks are located. To better illustrate where the constellation of gluconate peaks are expected in the 2D spectrum, we overlaid tumor spectra with that of the gluconate chemical standard (black/gray color). Figure 4c shows the spectrum of intact PGD-deleted xenografted tumor (NB1), where we observed the near-perfect overlap of the peaks in both dimensions with gluconate standard peaks. In contrast, Figure 4d shows the spectrum of the ex-vivo xenografted PGD-rescued tumor
(NB1-PGD), which was derived from NB1 cells; the PGD deletion was rescued with the atopic expression of PGD and effectively generated the NB1 cell line which is PGD wildtype. All the peaks associated with gluconate are absent in the spectrum of the PGD-rescued tumor. Figure 4e and 4f show $^1$H-$^{13}$C HSQC spectrum of PGD-wildtype tumor (D-423) and normal mouse brain where except one peak of H-C6-H doublet, which is obscured by the (-CH2-) metabolites, the rest of C-Hs peaks of gluconate are absent in both spectra. Supplementary Figure S6 shows the $^1$H projection of the gluconate standard, PGD-deleted, rescued and wildtype tumors from rows that we expect to observe gluconate peaks. Spectra of extracted rows of PGD deleted tumors show the same peaks as gluconate standard, while these peaks are absent in PGD wildtype tumors and normal brain. Altogether, we show that $^1$H-$^{13}$C HSQC is a robust technique to type PGD deletion status of cells and tumors, in addition to IDH mutations and elevated 2-HG. This is illustrative of the fact that this technique can type multiple oncometabolic aberrations simultaneously and agnostically.

Discussion

Cancer metabolism remains an aspirational target for precision oncology. Rapid identification of the subset of patients who are candidates for specific metabolism-based precision oncology drugs remains highly problematic. MRS has the potential to address this challenge, but the utility of this technique (as 1D $^1$H MRS) is currently limited to the detection and quantification of unusually abundant metabolites, which are uninformative for the purposes outlined above. The 1D $^1$H MRS sequence is employed routinely in the clinic; however, it suffers from broadening of peaks and lack of specificity. For example,
in the case of 2-HG detection, it is difficult to differentiate chemical shifts of metabolites like 2-HG from similarly structured metabolites such as glutamine and glutamate. Employing the spectral editing technique can improve the convolution/specificity problem, but it results in a sensitivity decrease and loss of global metabolite overview\textsuperscript{30}. The $^{13}$C spectrum has better specificity/spectral resolution compared to the $^1$H spectrum; however, it suffers from very low sensitivity due to the low natural abundance of $^{13}$C (1.1\%)\textsuperscript{31}. The sensitivity problem can be addressed by using the $^{13}$C hyperpolarized MRS\textsuperscript{32,33}. While this technique is useful for very specific questions, its application is limited to the choice of the hyperpolarized probe, and hence metabolic pathways\textsuperscript{21}. Chaumeil \textit{et al} used hyperpolarized 1-13C α-ketoglutarate to identify IDH mutant tumors non-invasively\textsuperscript{34}. However, the technique’s sensitivity is limited because of the presence of a 5-13C α-ketoglutarate peak, which has a chemical shift close to 1-13C 2-HG\textsuperscript{34}. Moreover, the use of α-ketoglutarate as the hyperpolarized probe can be restricted due to the hydrophilic nature of this molecule, which can limit its cell membrane permeability\textsuperscript{35}. Salamanca-Cardona \textit{et al} also used the hyperpolarized 1-13C glutamine to identify the \textit{IDH} mutant tumors\textsuperscript{36}. However, the transition of this technique to the clinic has not been forthcoming because of the short T1 half-life of 1-13C glutamine\textsuperscript{36} and slow glutamine uptake by cells\textsuperscript{31}. Correlation spectroscopy (COSY) has been employed \textit{in-vivo} setting to detect 2-HG\textsuperscript{30,37}. While this method is capable of detecting 2-HG, its application does not extend to detecting metabolites such as gluconate, which has chemical shifts close to the 4.7 ppm water signal.
Having noted the limitations with other spectroscopic methods, in this paper, we present data to support the case for 2D $^1$H-$^{13}$C HSQC in fulfilling the promises of MRS for precision oncology typing and metabolic profiling \textit{in vivo}.

Specifically, we present proof-of-feasibility of metabolite profiling by 2D HSQC NMR in an intact biological setting \textit{ex-vivo}. Compared to the 1D $^1$H spectrum of cells, the 2D $^1$H-$^{13}$C HSQC spectrum is more resolved, facilitating the assignment of specific peaks to specific metabolites since each 2D HSQC peak is defined by chemical shift information in both $^1$H and $^{13}$C axes. For example, in 2D $^1$H-$^{13}$C HSQC spectra of tumors, one can easily differentiate the lactate peak from the broad mobile lipid peak at (1.2 ppm, 30 ppm) which is elevated in high grade GBMs (necrosis)$^{29}$, while these two peaks cannot be differentiated in 1D $^1$H spectrum. We pioneer a phase-sensitive HSQC (HSQCETGPSISP3.2) pulse sequence to detect specific oncometabolite aberrations in biologically intact oncology samples for the purposes of precision oncology. The sequence not only yields a well-resolved 2D $^1$H-$^{13}$C HSQC spectrum but also distinguishes CH$_2$ from CH$_3$/CH, providing an additional layer of information. For proof-of-principle, we applied the technique to type tumors that are $IDH1$-mutant and characterized by detection of elevated 2-HG; to demonstrate the wider applicability to metabolic precision oncology, we further show that HSQC can readily identify tumors which are $PGD$-deleted, by detection of elevated 6-PG and gluconate. While here, we have demonstrated the utility of this technique for two specific metabolic aberrations caused by specific genomic alterations, this technique is applicable to the metabolomic typing of any other oncometabolite aberration whether genetic or epigenetic in nature.
While we see the present work as a stepping stone to the application of the phase-sensitive $^1$H-$^{13}$C HSQC sequence for precision oncology typing by MRS – and our data provide strong proof-of-principal for intact samples ex-vivo – legitimate questions may be raised as to whether $^1$H-$^{13}$C HSQC could be carried out in a full in vivo setting. We reply to this concern by noting that, in fact, in-vivo 2D $^1$H-$^{13}$C MRS method has already been pioneered by other groups$^{21,38-42}$, though our study is the first to illustrate its utility for oncometabolite typing. Kato et al detected $^{13}$C labeled temozolomide administrated in µM level in a mouse model$^{41}$, Chen et al detected glutamine and glutamate after administrating $^{13}$C labeled glucose$^{40}$, and the de Graaf lab characterized triglycerides in human adipose tissue using this technique$^{21}$. We are the first to demonstrate successful scans with the phased HSQC sequence as well as the successful oncometabolic typing of IDH1 mutation in intact tumors by HSQC. While throughout this work, we have only relied on natural abundance $^{13}$C, we leave open the possibility of enhancing sensitivity further through the use of specific $^{13}$C enriched substrates such as glucose and glutamine.

Besides its potential for IDH mutation typing in-vivo, the HSQC sequence developed here for ex-vivo samples could be applied essentially immediately in the (neuro)surgery setting to identify patients with IDH mutant tumors as well as delineating tumor versus normal brain tissue and in the future to type for other potentially targetable metabolic vulnerabilities as they are discovered. Because of the short NMR scan time and no requirement for sample preparation such as chemical extraction, this method would be well suited for the fast just-in-time surgery setting. The detailed metabolite information
could complement other imaging and genetic tests such as in-vivo MRS as well as genomic sequencing and IHC. The cellular structure of tumors is preserved in this method, which can be used for further genomic and histopathological analysis. Compared to the NMR spectrum of polarly extracted tumor solution, which only detects polar metabolites, the spectrum of the intact tumor has information about polar and apolar metabolites. Indeed, $^1$H-$^{13}$C HSQC has been employed to compliment $^1$H metabolic profiling on tumor extracts using very high magnetic field and large amount of samples or on intact tumors using high resolution magic angle spinning$^{43,44}$. We emphasize that the work here was performed in a standard NMR without signal enhancing features such as magic angle spinning and can be implemented in even non-specialist labs. In sum, $^1$H-$^{13}$C HSQC stands to dramatically expand our knowledge of tumor metabolism in vivo and to help realize the potential of metabolic precision oncology.

**Methods**

**Cell culture**: Cells were cultured at 37°C in 5% CO$_2$ in DMEM which contains 4.5 g/l of glucose and supplied by fetal bovine serum (Gibco/Life Technologies #16140-071) and 1% Pen Strep (Gibco/Life Technologies#15140-122) and 0.1% Amphotericin B (Gibco/Life Technologies#15290-018). The following established IDH1-mutant cancer cell lines were used in this study; cell lines are specified by mutation, followed by the cancer they originated. The cell lines used in this study were (with ExPasy cell-line ID numbers from Cellosaurus): HT-1080 (CVCL_0317, IDH1 R132C, fibrosarcoma), which express IDH1 at endogenous physiological levels, SNU-1079 (CVCL_5008, IDH1 R132C, intrahepatic cholangiocarcinoma) and RBE (CVCL_4896, IDH1 R132S, intrahepatic
cholangiocarcinoma), and COR-L105 (CVCL_1138, IDH1 R132C, lung adenocarcinoma). We also used engineered immortalized normal human astrocytes, NHA mIDH1 (IDH1 R132H mutant), which overexpress mutant IDH1. We also used the following IDH1 wildtype cell lines: D-423 (CVCL_1160), LN-319 (CVCL_3958), U-343 (CVCL_S471), G-59 (CVCL_N729), U-87 (CVCL_0022) and D-502 (CVCL_1162). Additionally, we used immortalized normal human astrocytes (NHA) which express the wildtype IDH1 gene. For the PGD-deletion/6-PG study, we used NB1 (CVCL_1440) cells (PGD-deleted) and NB1-PGD cells (NB1 cells with overexpressed PGD) from neuroblastoma.

**Preparation of NMR standards:** For assigning metabolite’s peaks in the spectrum, we prepared the 7.5 mM L-α-Hydroxyglutaric acid (Sigma Aldrich, 90790) sample in 90% PBS (Dulbecco’s phosphate-buffered saline, 21-031-CV) and 10% D₂O+3% TMS (Deuterium Oxide 99.9 atom % D, contains 0.75 wt %3-(trimethylsilyl)propionic -2,2,3,3-d₄ acid, sodium salt, Sigma Aldrich).

To choose the best ¹H-¹³C HSQC pulse program for our study, we prepared the 2-HG sample with 1 mM concentration in 100% D₂O. This low millimolar sample was chosen to evaluate which pulse program is capable of detecting metabolites with low concentration. For the PGD study, standard samples of 6-phosphogluconic acid trisodium salt (Sigma Aldrich, P7877) and D-gluconic acid sodium salt (Sigma Aldrich, G9005) were prepared at 7 mM concentration in 90% PBS and 10% D₂O. The standard sample concentration
was chosen to be in the millimolar level since it is the concentration we had expected in tumors and cells. The final pH of all prepared samples was approximately 7.

**Sample preparation for in vitro NMR analysis:** Cells were cultured in 15 cm plates. At 90% confluency, cells were harvested and washed once with 1x PBS to remove residual media. Cell number was measured using Trypan Blue (Corning, 25-900-Cl). A suspension of 170 μL cells (40-50 million cells) was then re-suspended in 500 μL of a solution containing 90% PBS with 10% D$_2$O with 3% TMS (Sigma Aldrich, 450510) and transferred to 5 mm NMR tubes. NMR tubes were sealed with parafilm. The spectral acquisition began immediately after sample preparation. Once measurements were complete, the cell number was measured again using Trypan Blue to verify cell viability during the duration of the experiment. Cells were then returned to 15 cm culture plates to verify normal growth patterns.

**Sample preparation for ex-vivo NMR analysis:** All procedures for animal studies were approved by the MD Anderson Animal Care and Use Committee. Nude mice were subcutaneously injected with 5 millions of cells harboring either IDH1 mutant or PGD-deletion as well as wildtype cells. When the tumor size became large (>1000 mm$^3$), the mouse carrying the subcutaneous tumor was euthanized. Immediately after tumor removal, fresh tumors were cut and placed in NMR tubes containing 300 μL of 90% PBS with 10% D$_2$O. The spectral acquisition began immediately after sample preparation. We also performed NMR on the snapped-frozen human GBM tumors. Collection of the human GBMs was done under the approved institutional review board (IRB) protocol by the MD Anderson (PA15-0940; PI: De Groot), where the informed written consent from
patients were obtained. We cut the human tumors into small pieces and place them into the Shigemi tube (Wilmad Labglass, BMS-005B) with 200uL of 90% PBS and 10% D2O, and we acquired the spectrum on them.

**Spectral acquisition:** All spectra were recorded on a Brucker Avance III HD 500 MHz spectrometer, which is equipped with a cryoprobe broadband observe probe, located at MD Anderson Cancer Center. Measurements were taken at 298K (25°C). A $^1$H NMR measurement (zg30 pulse sequence, flip angle 30°, 1-second relaxation delay, 16 scans) was taken for a duration of 1 min and 17 s immediately before $^1$H-$^{13}$C HSQC spectral acquisition. 2D NMR measurements were obtained using the HSQCEDETGPSISP2.3 pulse program in the Bruker experiment library (1.5-second relaxation delay, F1=2048, F2=256, 4 scans) for a duration of 29 min and 44 s.

The spectra were analyzed using Bruker TopSpin 3.1. For the 1D $^1$H spectra, we did 1st and 2nd order phase correction followed by automatic baseline correction. 2D $^1$H-$^{13}$C HSQC spectra were phase-corrected as needed, and baseline adjusted at the F1 and F2 axis using abs1 and abs2 commands. Counter level increments were also adjusted to the 1.1, for a total of 28 levels.

The 1D $^1$H projections of the $^1$H-$^{13}$C HSQC spectra were extracted using the rsr command and specifying the desired row number. Signal to noise ratio (SNR) was obtained by defining the desired signal region by sigf1 and sigf2 commands on Topspin and then using the SINO command. To find the signal to noise ratio for negative peaks, we first
adjusted the negative phased peaks to positive and then select region of interest using the SINO command.

**Polar Metabolomic Profiling:** We used mass spectroscopy technique to confirm high level of 2-HG and 6-PG/gluconate in IDH1 mutant and PGD-deleted cells and tumors. We used Beth Israel Deaconess Medical center (BIDMC) CORE to profile polar metabolites. To extract polar metabolites from cells, we removed media from 10 cm dishes of cells with 90% confluency, and washed with cold PBS, and removed the PBS completely. We then placed dishes into dry ice and added 4 ml of -80°C pre-cooled 80% methanol in cells and incubated them for 20 min in -80°C. Then, we scrapped the cells and took the cells lysate into the pre-cooled tubes and spun down cell’s lysate in 4°C at 17,000 x g for 5 min. We then removed the supernatant from the cell pallets and speedvaced it to get the pallets and sent it to BIDMC.

To extract frozen human and xenografted mouse tumors, we put 50 mg of tumors in pre-cooled Fisher Tube #02-681-291 with Qiagen steel beads. Then, we added 1 ml of -80°C pre-cooled methanol to each tube. To make homogenous solutions, we shook tubes with Qiagen Tissue Lyser at 28 Hz for 45 s in multiple rounds. We then adjusted the final volume of each sample based on 50 mg tissue/2 ml of 80% methanol and incubated samples at -80°C for 24 hrs. After 24 hours of incubation at 80°C, we vortexed samples and spun them down at 17,000 x g at 4°C for 5 min. We then transferred the supernatant to a new tube and speedvaced it to dryness, and sent the pallets to BIDMC.
Figure 1: The H-C3-H peaks of 2-HG are uniquely detected in live IDH1-mutant cells and are eliminated by mutant-IDH1 specific inhibitor treatment. (a) Live cancer cells in suspension were placed in an NMR tube for NMR spectral acquisition in 90% PBS and 10% D2O. (b-e) Phase-sensitive $^1$H-$^{13}$C HSQC spectra using HSQCEDETGPSISP2.3 pulse sequence, where the first color code in each spectrum depicts positive phase peaks (CH$_3$ and CH, e.g., brown in a) and the second color code shows negative phase peaks (CH$_2$, e.g., pink in a), acquired using 500 MHz Bruker AVANCE III NMR. The black dashed square indicates magnification of the region of the spectrum around H-C3-H peaks of 2-HG, and the red dashed box shows where H-C3-H peaks of 2-HG would be expected in the biological samples (b-e). In the $^1$H-$^{13}$C HSQC spectrum, the protons which are directly bounded with $^{13}$C atoms are detected ($^1$H-chemical shift in the x-axis, $^{13}$C-chemical shift in y-axis), these carbons and protons are labeled in the 2-HG structure and 2-HG peaks are annotated in the spectrum (a). (b) The spectrum of 2-HG chemical standard (7.5 mM) with peak assignments; (c) The $^1$H-$^{13}$C HSQC spectrum of live R132C IDH1 mutant cells (HT-1080). The presence of 2-HG peaks is readily evident in the HSQC spectrum of HT-1080 cells by the H-C3-H peaks. The C2-H peak is very close to the highly abundant myo-inositol peak and barely distinguishable. The H-C4-H peak is obscured by the broad (-CH2-) lipid peak. However, H-C3-H peaks can be easily detected. (d) The spectrum of IDH1 mutant cells (HT-1080) treated with 10 µM IDH1 inhibitor (AGI-5198) for 48 hrs. The H-C3-H peaks of 2-HG disappeared, consistent with the significant reduction in the amount of 2-HG. (e) In contrast to mutant IDH1 cancer
cells (HT-1080), the spectrum of live IDH1 wildtype cells (D-423) shows a complete absence of H-C3-H peaks of 2-HG.

**Figure 2:** The H-C3-H peaks of 2-HG are detected in *ex-vivo* IDH1-mutant but not *IDH1-WT* xenografted tumors nor normal brain. (a) Xenografted tumors were excised and immediately placed in an NMR tube with PBS 10% D2O. The phase-sensitive 1H-13C HSQC spectrum was acquired using the HSQCEDETGPSISP2.3 pulse sequence with the same parameters and instrument as used in Figure 1. (b) The spectrum of *ex-vivo* IDH1 mutant xenograft tumor (HT-1080) shows the presence of 2-HG. As in Figure 1 for live cells, the C2-H peak of 2-HG is very close to the myo-inositol peak, which cannot be distinguished. The broad (-CH2-) lipid peak obscures the H-C4-H peak of 2-HG. However, H-C3-H peaks can be easily detected and are unobscured by other metabolites (pink-dashed box). (c-e) As expected, the H-C3-H peaks of 2-HG are absent (pink dashed box) in the spectra of the *ex-vivo* IDH1-wildtype xenograft tumors (D-423 and G-59) and mouse brain.

**Figure 3:** The H-C3-H peaks of 2-HG are uniquely detected in *IDH1*-mutant but not *IDH1*-wildtype human GBM *ex-vivo*. (a) Flash-frozen GBM tumor resection specimens kept at -80°C were cut into ~150 mg pieces and placed in a Shigemi NMR tube with 90% PBS and 10% D2O for NMR spectroscopy studies. (b and c) Phase-sensitive 1H-13C HSQC spectrum acquired by HSQCEDETGPSISP2.3 pulse sequence, where the first color code in each spectrum shows the peaks which have positive phase (CH₃ and CH) and the second color code shows the peaks which have negative phase (CH₂). The black
square in the spectrum magnifies the region of the spectrum where H-C3-H peaks of 2-HG are located. The red dashed box shows where we expect to see H-C3-H peaks of 2-HG in the spectrum. (b) The spectrum of an IDH1-mutant primary GBM, with the H-C3-H peaks, clearly detectable. The C2-H and H-C4-H are obscured by myo-inositol and (-CH2-) lipid peaks. (c) The spectrum of an IDH1-wildtype primary GBM, with no detectable H-C3-H peaks. (d) The $^1$H projection of H-C3-H peaks of 2-HG from $^1$H-$^{13}$C HSQC spectrum of 2-HG standard, mutant IDH1-tumors, IDH1-wildtype tumors and normal mouse brain. $^1$H projection extracted from the 2D HSQC spectrum of mutant IDH1-tumors shows the negatively phased doublet associated with H-C3-H peaks of 2-HG. These two peaks are absent in all IDH1-wildtype tumors and normal mouse brain. The spectra are normalized to the noise level. (e) Levels of 2-HG in the IDH1-mutant versus IDH1-wildtype human GBMs obtained by mass-spec. 2-HG accumulates >20-fold inside IDH1-mutant tumors compared to wildtype ones. This figure verifies that H-C3-H are not only uniquely observed in IDH1-mutant cells and xenograft tumors, but also in primary GBM tumors.

Figure 4: Specific HSQC detection of gluconate exclusively in PGD-deleted xenografted tumors ex-vivo. (a) PGD (6-phosphogluconate dehydrogenase) is a key enzyme of the oxidative pentose phosphate shunt, and that can be collaterally deleted in specific cancers as part of the 1p36 tumor suppressor locus$^{11,12}$. High accumulation of the PGD substrate, 6-phosphogluconate, and hydrolysis product, gluconate, have been previously documented by our group in tumors with PGD-deletions by mass spec metabolomics$^{12}$. (b-f) $^1$H-$^{13}$C HSQC spectra acquired in a 500 MHz NMR spectrometer using the HSQCEDETGPSISP2.3 pulse program, where the first color code in each
spectrum shows the peaks which have a positive phase (CH$_3$ and CH), and the second color code shows the peaks which have negative phase (CH$_2$). (b) The molecular structure of gluconate and the $^1$H-$^{13}$C HSQC spectrum of a gluconate standard at 7 mM concentration in PBS 10% D$_2$O. (c) The $^1$H-$^{13}$C HSQC spectrum of a PGD-deleted xenografted tumor (NB1) ex-vivo. In the black box, the zoomed-in spectrum is overlaid with gluconate peaks from the standard in a (black and gray). Alignment of the peak’s gluconate standard (black/gray) with the xenografted tumor indicates the successful detection of gluconate. (d-e) $^1$H-$^{13}$C HSQC spectra of an ex-vivo PGD-rescued (NB1-pCMV-PGD) and wildtype (D-423) xenografted tumors. In the black box in the figure, the zoomed-in spectrum is overlaid with gluconate peaks (black/gray) to demonstrate where those peaks are. Although one of the gluconate peaks is obscured with another metabolite, other peaks show unique intensity in PGD-deleted tumors. (f) The $^1$H-$^{13}$C HSQC spectrum of mouse normal brain. Same as PGD wildtype and rescued tumors, except for the C6-H peak of gluconate, the rest of gluconate peaks were not detected in the spectrum.

Table 1: The summery of all cell lines that were identified with the IDH1 mutation and PGD-deletion status by $^1$H-$^{13}$C HSQC technique. We looked at five different IDH1 mutant cell lines (in-vitro and in-vivo) that overproduce 2-HG due to this mutation. We were able to detect H-C3-H peaks of 2-HG in all these cell lines (in-vitro and in-vivo). Then we treated them with the mutant IDH1 inhibitor (AGI-5198), which shows significant effects in reducing 2-HG production, and the H-C3-H peaks of 2-HG disappeared after the treatment. The spectrum of live IDH1 wildtype cells shows a complete absence of H-
C3-H peaks of 2-HG (in-vitro and in-vivo). We also looked at the PGD-deleted cell line (NB1), which significantly accumulates gluconate due to this deletion. We were able to detect gluconate peaks in the spectrum of live cells and ex-vivo xenografted tumors. These peaks are absent in the spectra of PGD-rescued and wildtype cells and tumors.

Acknowledgements
This work was supported by The University of Texas MD Anderson Cancer Center/Glioblastoma Moon Shot, the Brockman Medical Research Foundation, the SPORE in Brain Cancer (2P50CA127001) funds, the American Cancer Society Research Scholar Award RSG-15-145-01-CDD, the National Comprehensive Cancer Network – Young Investigator Award YIA170032, the Andrew Sabin Family Foundation Fellows Award and the US National Institutes of Health (1R21CA226301) to F.L.M. The authors would like to thank Lisa Norberg and Kristin Alfaro-Munoz for help obtaining frozen GBM specimens. We would like to thank Dr. John Asara for metabolite profiling data, Dr. James Bankson, Dr. Mark D. Pagel, Dr. Samuel Einstein, Dr. Seth T Gammon and Dr. Niki Zacharias Millward for their insights into this project. We will also thank Dr. Kumaralal K. Kaluarachchi, the manager of NMR facility at U.T.M.D. Anderson. We would also like to thank Dr. Anna Pawliczek, Dr. Dimitra Georgiou, Yu-Hsi Lin and Jorge Delacerda for their editorial and technical assistance.

Author contributions
Y.B. performed metabolomic sample preparation, NMR studies, and data analysis; Y.B., S.K. and K.A. prepared xenografted mouse tumors; J.J.A. performed western blots;
J.D.G. and J.T.H. shared genomic data and primary tumor samples; Y.B. and F.L.M. conceived the study; Y.B., V.C.Y. and F.L.M. wrote the paper.

**Declarations of interest**

The authors declare no conflicts.

**References**

1. Lowery, M. A. *et al.* Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. *Lancet Gastroenterol Hepatol* **4**, 711-720, doi:10.1016/s2468-1253(19)30189-x (2019).

2. Molina, J. R. *et al.* An inhibitor of oxidative phosphorylation exploits cancer vulnerability. *Nat Med* **24**, 1036-1046, doi:10.1038/s41591-018-0052-4 (2018).

3. Gao, G. *et al.* PRMT1 loss sensitizes cells to PRMT5 inhibition. *Nucleic Acids Res* **47**, 5038-5048, doi:10.1093/nar/gkz200 (2019).

4. Cohen, A. L., Holmen, S. L. & Colman, H. IDH1 and IDH2 mutations in gliomas. *Curr Neurol Neurosci Rep* **13**, 345, doi:10.1007/s11910-013-0345-4 (2013).

5. Losman, J. A. & Kaelin, W. G., Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. *Genes Dev* **27**, 836-852, doi:10.1101/gad.217406.113 (2013).

6. Losman, J. A. *et al.* (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. *Science* **339**, 1621-1625, doi:10.1126/science.1231677 (2013).
Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature* **483**, 484-488, doi:10.1038/nature10898 (2012).

Auezova, R. et al. Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients. *Cancer Manag Res* **11**, 3227-3236, doi:10.2147/cmar.S195754 (2019).

Yan, H. et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* **360**, 765-773, doi:10.1056/NEJMoa0808710 (2009).

Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. *Nature* **488**, 337-342, doi:10.1038/nature11331 (2012).

Muller, F. L., Aquilanti, E. A. & DePinho, R. A. Collateral Lethality: A new therapeutic strategy in oncology. *Trends Cancer* **1**, 161-173, doi:10.1016/j.trecan.2015.10.002 (2015).

Sun, Y. et al. Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. *Cell Rep* **26**, 469-482.e465, doi:10.1016/j.celrep.2018.12.043 (2019).

Serkova, N. J. & Brown, M. S. Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers. *Bioanalysis* **4**, 321-341, doi:10.4155/bio.11.320 (2012).

Leather, T., Jenkinson, M. D., Das, K. & Poptani, H. Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas. *Metabolites* **7**, doi:10.3390/metabo7020029 (2017).
15 Nagashima, H. et al. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. *Neuro Oncol* **18**, 1559-1568, doi:10.1093/neuonc/now090 (2016).

16 Emir, U. E. et al. Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. *Cancer Res* **76**, 43-49, doi:10.1158/0008-5472.Can-15-0934 (2016).

17 Pope, W. B. et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. *J Neurooncol* **107**, 197-205, doi:10.1007/s11060-011-0737-8 (2012).

18 Choi, C. et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med* **18**, 624-629, doi:10.1038/nm.2682 (2012).

19 Choi, C. et al. A comparative study of short- and long-TE (1)H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. *NMR Biomed* **26**, 1242-1250, doi:10.1002/nbm.2943 (2013).

20 Andronesi, O. C. et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. *J Clin Invest* **123**, 3659-3663, doi:10.1172/jci67229 (2013).

21 de Graaf, R. A., De Feyter, H. M. & Rothman, D. L. High-sensitivity, broadband-decoupled (13) C MR spectroscopy in humans at 7T using two-dimensional heteronuclear single-quantum coherence. *Magn Reson Med* **74**, 903-914, doi:10.1002/mrm.25470 (2015).
Mandal, P. K. & Majumdar, A. A comprehensive discussion of HSQC and HMQC pulse sequences. *Concepts in Magnetic Resonance Part A: An Educational Journal* **20**, 1-23 (2004).

Rohle, D. *et al.* An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science* **340**, 626-630, doi:10.1126/science.1236062 (2013).

Boyer, R. D., Johnson, R. & Krishnamurthy, K. Compensation of refocusing inefficiency with synchronized inversion sweep (CRISIS) in multiplicity-edited HSQC. *J Magn Reson* **165**, 253-259, doi:10.1016/j.jmr.2003.08.009 (2003).

Palmer III, A. G., Cavanagh, J., Wright, P. E. & Rance, M. Sensitivity improvement in proton-detected two-dimensional heteronuclear correlation NMR spectroscopy. *Journal of Magnetic Resonance (1969)* **93**, 151-170 (1991).

Schleucher, J. *et al.* A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients. *Journal of biomolecular NMR* **4**, 301-306 (1994).

Li, H. *et al.* The landscape of cancer cell line metabolism. *Nat Med* **25**, 850-860, doi:10.1038/s41591-019-0404-8 (2019).

Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. *Nat Rev Cancer* **11**, 85-95, doi:10.1038/nrc2981 (2011).

Chung, Y. L., Madhu, B. & Griffiths, J. R. Metabolism and Metabolomics by MRS. *eMagRes*, 689-698 (2007).

Andronesi, O. C. *et al.* Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance
spectroscopy. *Sci Transl Med* **4**, 116ra114, doi:10.1126/scitranslmed.3002693 (2012).

31 Najac, C. & Ronen, S. M. MR Molecular Imaging of Brain Cancer Metabolism Using Hyperpolarized 13C Magnetic Resonance Spectroscopy. *Top Magn Reson Imaging* **25**, 187-196, doi:10.1097/rmr.0000000000000104 (2016).

32 Siddiqui, S. *et al.* The use of hyperpolarized carbon-13 magnetic resonance for molecular imaging. *Adv Drug Deliv Rev* **113**, 3-23, doi:10.1016/j.addr.2016.08.011 (2017).

33 Ardenkjaer-Larsen, J. H. *et al.* Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. *Proc Natl Acad Sci U S A* **100**, 10158-10163, doi:10.1073/pnas.1733835100 (2003).

34 Chaumeil, M. M. *et al.* Non-invasive in vivo assessment of IDH1 mutational status in glioma. *Nat Commun* **4**, 2429, doi:10.1038/ncomms3429 (2013).

35 MacKenzie, E. D. *et al.* Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. *Mol Cell Biol* **27**, 3282-3289, doi:10.1128/mcb.01927-06 (2007).

36 Salamanca-Cardona, L. *et al.* In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors. *Cell Metab* **26**, 830-841.e833, doi:10.1016/j.cmet.2017.10.001 (2017).

37 Verma, G. *et al.* Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla. *J Transl Med* **14**, 274, doi:10.1186/s12967-016-1035-1 (2016).
38 Watanabe, H. et al. Human brain glucose metabolism mapping using multislice 2D 1H-13C correlation HSQC spectroscopy. *Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine* **43**, 525-533 (2000).

39 Watanabe, H. et al. 3D localized 1H-13C heteronuclear single-quantum coherence correlation spectroscopy in vivo. *Magn Reson Med* **43**, 200-210, doi:10.1002/(sici)1522-2594(200002)43:2<200::aid-mrm6>3.0.co;2-h (2000).

40 Chen, H. et al. Comparison of direct (13)C and indirect (1)H-[(13)C] MR detection methods for the study of dynamic metabolic turnover in the human brain. *J Magn Reson* **283**, 33-44, doi:10.1016/j.jmr.2017.08.004 (2017).

41 Kato, Y., Okollie, B. & Artemov, D. Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. *Magn Reson Med* **55**, 755-761, doi:10.1002/mrm.20831 (2006).

42 de Graaf, R. A., Brown, P. B., Mason, G. F., Rothman, D. L. & Behar, K. L. Detection of [1,6-13C2]-glucose metabolism in rat brain by in vivo 1H-[13C]-NMR spectroscopy. *Magn Reson Med* **49**, 37-46, doi:10.1002/mrm.10348 (2003).

43 Park, G. H. J., Yang, S. H. & Baek, H. M. 900MHz 1H-/13C-NMR analysis of 2-hydroxyglutarate and other brain metabolites in human brain tumor tissue extracts. *PLoS One* **13**, e0203379, doi:10.1371/journal.pone.0203379 (2018).

44 Martinez-Bisbal, M. C. et al. 1H and 13C HR-MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas. *NMR Biomed* **17**, 191-205, doi:10.1002/nbm.888 (2004).
Figure 1

(a) Pure 2-hydroxyglutarate standard

(b) R132C IDH1 mutant cells (HT-1080)

(c) IDH1-wildtype cells (D-423)

(d) IDH1-mutant cells (HT-1080) treated with AGI-5198

(e) IDH1-wildtype cells (D-423)
| Cell line          | Cell type                  | IDH1 status | H-C3-H2-HG | PGD-status | Gluconate peak constellation | Biological replicates-cell lines in-vitro | Biological replicates-ex-vivo xenografted tumors |
|--------------------|----------------------------|-------------|------------|------------|------------------------------|-----------------------------------------|------------------------------------------------|
| HT-1080            | Fibrosarcoma               | R132C       | Yes        | WT         | No                           | 7                                       | 8                                              |
| SNU-1079           | Cholangiocarcinoma         | R132C       | Yes        | WT         | No                           | 1                                       | -                                              |
| RBE                | Cholangiocarcinoma         | R132S       | Yes        | WT         | No                           | 2                                       | -                                              |
| COR-L105           | Adenocarcinoma             | R132C       | Yes        | WT         | No                           | 1                                       | -                                              |
| NHA IDH1           | Normal Human astrocytes overexpressing mIDH1 | R132H       | Yes        | WT         | No                           | 2                                       | -                                              |
| HT-1080 + mIDH1 inhibitor | Fibrosarcoma               | R132C       | No         | WT         | No                           | 2                                       | -                                              |
| SNU-1079+mIDH1 inhibitor | Cholangiocarcinoma         | R132C       | No         | WT         | No                           | 2                                       | -                                              |
| RBE+mIDH1 inhibitor | Cholangiocarcinoma         | R132S       | No         | WT         | No                           | 2                                       | -                                              |
| NHA IDH1+mIDH1 inhibitor | Normal Human astrocytes overexpressing mIDH1 | R132H       | No         | WT         | No                           | 1                                       | -                                              |
| NHA PLVX           | Normal Human astrocytes    | WT          | No         | WT         | No                           | 2                                       | -                                              |
| D-423              | Glioma                     | WT          | No         | WT         | No                           | 5                                       | 8                                              |
| LN-319             | Glioma                     | WT          | No         | WT         | No                           | 2                                       | -                                              |
| U-343              | Glioma                     | WT          | No         | WT         | No                           | 2                                       | -                                              |
| G-59               | Glioma                     | WT          | No         | WT         | No                           | -                                       | 1                                              |
| U-87               | Glioma                     | WT          | No         | WT         | No                           | -                                       | 2                                              |
| D-502              | Glioma                     | WT          | No         | WT         | No                           | 2                                       | -                                              |
| NB1                | Neuroblastoma              | WT          | No         | Deleted    | YES                          | 3                                       | 6                                              |
| NB1 PGD            | Neuroblastoma              | WT          | No         | Rescued    | No                           | 2                                       | 5                                              |
Figure 2

(b) R132C IDH1-mutant xenograft (HT-1080)
- CH₃ and CH
- CH₂

(c) IDH1-wildtype xenograft (D-423)
- CH₃ and CH
- CH₂

(d) IDH1-wildtype xenograft (G-59)
- CH₃ and CH
- CH₂

(e) Normal brain
- CH₃ and CH
- CH₂

- H-C3-H not observed
Figure 3

- a: Resected human GBM
- b: R132H IDH1-mutant human GBM tumor
- c: IDH1-wildtype human GBM tumor
- d: 1H projection of H-C3-H peaks of 2-HG from (1H-13C) HSQC spectrum
- e: 2-Hydroxyglutarate (ions count x10)
